All News
Filter News
Found 104 articles
-
The Association of Black Cardiologists Issues Prior Authorization Resource Kits for Healthcare Providers
8/10/2018
The development of administrative tools for a standardized and centralized process increases access and positively impacts minority and high-risk populations.
-
Despite market volatility, ongoing debates about drug pricing, and various scandals such as the Theranos debacle, everything Martin Shkreli touches, and Novartis paying President Trump’s attorney Michael Cohen $1.2 million for access to the president, it hasn’t slowed down biotech startups or inv...
-
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
-
Endo Reports Fourth-Quarter And Full-Year 2017 Financial Results
2/27/2018
Fourth-quarter 2017 revenues of $769 million; Full-year 2017 revenues of $3,469 million
-
Axovant shares plunged after Hung abruptly resigned as CEO and also stepped down from his seat on the company board of directors.
-
BridgeBio stepped in to take over the drug and also launch a subsidiary, QED Therapeutics, to drive the development of infigratinib.
-
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging
1/19/2018
The program will leverage Ligand’s patented Captisol technology, as well as data and intellectual property obtained through its acquisition of Verrow Pharmaceuticals.
-
Juno Explodes on Celgene Takeover Rumors
1/17/2018
The rumors have caused Juno's stock to rocket more than 50 percent to $68.80 in premarket trading. -
Regeneron indicated that because of disappointing results for two Phase II trials, it was ending its development of angiopoietin2 antibody nesvacumab as an addition to Eylea.
-
CAR-T is a hot new area and there are companies hot on Gilead's tail, namely Juno, in a partnership with Celgene, and Novartis.
-
Endo Reports Third-Quarter 2017 Financial Results
11/10/2017
Revenues of $787M, an 11 percent decrease compared to third-quarter 2016 revenues of $884M.
-
Astra signed a licensing deal with Mereo BioPharma to out license the oral inhibitor of neutrophil elastase to the smaller Mereo.
-
GlaxoSmithKline to Shift Neuro R&D Out of China to Philadelphia Research Hub
8/7/2017
-
Uncertainty Hits as Roche is Dealt Multiple Clinical Trial Setbacks
7/21/2017
-
Rumor Alert: AstraZeneca PLC CEO to Become Teva's New Leader
7/14/2017
-
Bay Area's Coherus Dealt Another Blow as Daiichi Sankyo Discontinues Work on RA Drug
7/6/2017
-
Unknown Nanjing Legend Emerges as a CAR-T Phenom at ASCO
6/7/2017
-
Ligand Announces Aziyo Biologics Acquires Commercial Products From Partner CorMatrix Cardiovascular
6/1/2017
-
GlaxoSmithKline Apparently Prepping to Buy Out Novartis Consumer Health Joint Venture Stake for $10.3 Billion
5/16/2017
-
FDA Just Rejected Eli Lilly, Incyte's Rheumatoid Arthritis Drug Baricitinib
4/18/2017